Nanometer drug of metapristone inhibits cancer metastasis in breast cancer cells in vitro and in viv

来源 :The 6th International Conference on Nanoscience and Technolo | 被引量 : 0次 | 上传用户:play5
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Aim: The present explored the effects of metapristone,a major biological active metabolite of mifepristone(RU486),on the tumor growth and metastasis of MCF-7 and 4T1 murine mammary carcinoma in vitro and in vivo [1,2],and underlying mechanisms was elucidated.
其他文献
The insufficient cellular uptake of nanocarriers and their slow drug release have become major obstacles for achieving satisfactory anticancer outcomes in nano-medicine therapy.
The human mutT homologue MTH1,a nucleotide pool sanitizing enzyme,represents a vulnerability factor and an attractive target for anticancer therapy.
Although many multifunctional drug-loaded nanomaterials have been designed to increase drug delivery into tumor cells,only limited improvement has been achieved to overcome multi-layered stromal cell
Purpose-Peptides have emerged as promising cancer therapeutics characterized by low toxicity,high specificity,and ease of synthesis.The short half-life of peptide therapeutics stands as the most chall
Highly crosslinked proteins,including keratin and soyprotein containing 7%and 1.2%of cysteine respectively,were electrospun into three-dimensional(3D)ultrafine fibrous scaffolds for biomedical applica
Previous studies mainly attributed the improved anti-tumor effect of nanocarriers-based drug delivery systems to its favorable pharmacokinetics,specific tumor targeting and drug accumulation in tumor
We have synthesised a range of novel protein-polymer surfactant nanoconjugates by systematic surface modification.Using dynamic light scattering and UV-visible spectroscopy we have demonstrated that t
Polymeric nanoparticle coated with intact red blood cell(RBC)membrane has emerged as biomimetic toxin nanosponges that absorb membrane-damaging toxins and divert them away from their cellular targets.
An amphiphilic hyaluronic acid derivate,redox-sensitive hyaluronic acid-deoxycholic acid(HA-ss-DOCA)conjugate,was successfully developed.
Erlotinib is an-EGFR-specific TKI that functiones as an antiproliferative agent and is an inducer of apoptosis and reversible cell cycle arrest[1].